Skip to main content
GoodMoatv1.1
Sign in
AMGN logo

AMGN

CompareEarnings: May 31, 2026

AMGEN Inc

Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - General

Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions. Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ®, and it is also part of the Nasdaq-100 Index ®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

Did you know?

Profit margin of 21.0% — that's well above average.

Current Price

$347.94

-1.51%

GoodMoat Value

$230.03

33.9% overvalued
Profile
Valuation (TTM)
Market Cap$187.36B
P/E24.30
EV$233.82B
P/B21.64
Shares Out538.48M
P/Sales5.10
Revenue$36.75B
EV/EBITDA13.78

AMGEN Inc (AMGN) Company Profile

GoodMoat Analysis

Based on data as of March 26, 2026

Amgen is a large, established biopharmaceutical company with a portfolio of blockbuster drugs and a strong pipeline. However, a value investor must weigh its high profitability and dividend against significant debt, patent expirations, and a valuation that appears high relative to the GoodMoat target.

Read full analysis
Amgen Inc. (AMGN) is a global biotechnology company that discovers, develops, manufactures, and markets human therapeutics for serious illnesses. Its customers are primarily healthcare providers and patients, with its products sold globally. The company's moat, assessed via the GoodMoat framework, is built on several factors. It scores highly on Regulatory Barriers (criterion 5) through patents protecting its key drugs, and on Technology Leadership (criterion 9) via its complex biologics manufacturing. It also demonstrates Pricing Power (criterion 13) for its innovative therapies. However, it faces a high-confidence Red Flag (criterion 8) in Competitive Erosion as major patents expire, opening the door to biosimilar competition that can erode sales and margins. Another high-confidence Red Flag is its significant Debt/Equity ratio of 6.3, far exceeding the framework's favourable threshold of less than 1.0x Debt/EBITDA. For a value investor, the attraction lies in its high profitability (21% net margin, 89.1% ROE) and 2.69% dividend yield. The caution stems from its elevated valuation—a P/E of 24.7 and a market price of $353.93, which is 54% above the GoodMoat target of $230.03—coupled with the substantial debt load and the ongoing need to replace revenue from maturing products.

AMGN Company Information

Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today.

Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions. Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes.

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ®, and it is also part of the Nasdaq-100 Index ®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

Sector

Healthcare

Industry

Drug Manufacturers - General

Exchange

NASDAQ

Country

California, USA

AMGN Key Officers

Key officers data coming soon

AMGN Company Profile

AMGEN Inc (AMGN) is a Healthcare company in the Drug Manufacturers - General industry, listed on NASDAQ. Headquartered in California, USA.

Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions. Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ®, and it is also part of the Nasdaq-100 Index ®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

Market capitalization: $187.36B. Shares outstanding: 538.5M. Dividend yield: 2.73%.

View the complete company profile for AMGEN Inc on GoodMoat, including key officers, financial metrics, sector classification, and investment analysis tools. Use the profile alongside GoodMoat's DCF calculator, fair value models, and quality score to evaluate whether AMGN is a sound investment opportunity.